Trevi Cash Per Share vs Pfcf Ratio Analysis

TRVI Stock

USD 2.91 0.18 6.59%

Trevi Therapeutics financial indicator trend analysis is much more than just breaking down Trevi Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Trevi Therapeutics is a good investment. Please check the relationship between Trevi Therapeutics Cash Per Share and its Pfcf Ratio accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Trevi Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

For more detail on how to invest in Trevi Stock please use our How to Invest in Trevi Therapeutics guide.

Cash Per Share vs Pfcf Ratio

Cash Per Share vs Pfcf Ratio Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Trevi Therapeutics Cash Per Share account and Pfcf Ratio. At this time, the significance of the direction appears to have strong relationship.

The correlation between Trevi Therapeutics' Cash Per Share and Pfcf Ratio is 0.67. Overlapping area represents the amount of variation of Cash Per Share that can explain the historical movement of Pfcf Ratio in the same time period over historical financial statements of Trevi Therapeutics, assuming nothing else is changed. The correlation between historical values of Trevi Therapeutics' Cash Per Share and Pfcf Ratio is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash Per Share of Trevi Therapeutics are associated (or correlated) with its Pfcf Ratio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Pfcf Ratio has no effect on the direction of Cash Per Share i.e., Trevi Therapeutics' Cash Per Share and Pfcf Ratio go up and down completely randomly.

Correlation Coefficient

0.67

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Cash Per Share

Pfcf Ratio

Most indicators from Trevi Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Trevi Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Trevi Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

For more detail on how to invest in Trevi Stock please use our How to Invest in Trevi Therapeutics guide.The Trevi Therapeutics' current Tax Provision is estimated to increase to about (66.5 K). The current Selling General Administrative is estimated to decrease to about 7.6 M

Trevi Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Retained Earnings	Accounts Payable	Cash	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Long Term Debt Total	Other Current Assets	Total Liab	Short Long Term Debt	Total Current Assets	Short Term Debt	Common Stock	Property Plant Equipment	Short Long Term Debt Total	Property Plant And Equipment Net	Net Debt	Non Current Assets Total	Non Currrent Assets Other
Total Assets		0.69	-0.54	0.98	-0.8	0.88	-0.86	0.83	0.48	-0.02	0.0	0.57	0.69	-0.02	0.67	-0.54	-0.2	1.0	-0.57	0.58	0.64	0.06	0.56	-0.2	0.48	0.1
Other Current Liab	0.69		-0.31	0.63	-0.83	0.82	-0.74	0.88	0.64	-0.14	0.53	0.59	0.72	0.31	0.5	-0.14	-0.02	0.69	-0.45	0.31	0.74	0.35	0.49	-0.44	0.38	0.02
Total Current Liabilities	-0.54	-0.31		-0.67	0.31	-0.5	0.6	-0.49	-0.77	-0.42	-0.08	-0.7	-0.76	-0.09	-0.4	0.92	0.81	-0.53	0.98	-0.67	-0.77	0.16	-0.54	0.54	-0.75	-0.6
Total Stockholder Equity	0.98	0.63	-0.67		-0.73	0.85	-0.85	0.79	0.54	0.08	-0.03	0.62	0.75	-0.03	0.66	-0.68	-0.34	0.98	-0.68	0.66	0.68	-0.04	0.59	-0.27	0.56	0.2
Other Liab	-0.8	-0.83	0.31	-0.73		-0.93	0.9	-0.88	-0.5	0.31	-0.1	-0.69	-0.55	0.08	-0.78	0.23	-0.03	-0.8	0.4	-0.29	-0.51	-0.27	-0.68	0.25	-0.43	0.15
Net Tangible Assets	0.88	0.82	-0.5	0.85	-0.93		-0.92	0.82	0.61	-0.25	0.15	0.81	0.72	0.09	0.83	-0.44	-0.12	0.88	-0.6	0.41	0.69	0.03	0.8	-0.43	0.59	-0.04
Retained Earnings	-0.86	-0.74	0.6	-0.85	0.9	-0.92		-0.85	-0.52	-0.04	0.07	-0.78	-0.62	0.19	-0.88	0.52	0.35	-0.85	0.66	-0.64	-0.6	-0.09	-0.81	0.24	-0.75	-0.25
Accounts Payable	0.83	0.88	-0.49	0.79	-0.88	0.82	-0.85		0.62	0.0	0.28	0.55	0.7	0.06	0.52	-0.33	-0.21	0.83	-0.55	0.44	0.7	0.47	0.43	-0.23	0.41	0.13
Cash	0.48	0.64	-0.77	0.54	-0.5	0.61	-0.52	0.62		-0.03	0.61	0.77	0.9	0.52	0.28	-0.59	-0.39	0.47	-0.82	0.24	0.93	0.08	0.49	-0.85	0.46	0.16
Other Assets	-0.02	-0.14	-0.42	0.08	0.31	-0.25	-0.04	0.0	-0.03		-0.28	-0.12	0.11	-0.34	-0.12	-0.45	-0.82	-0.03	-0.36	0.74	0.11	-0.19	-0.11	0.16	0.42	0.92
Long Term Debt	0.0	0.53	-0.08	-0.03	-0.1	0.15	0.07	0.28	0.61	-0.28		0.16	0.49	0.91	-0.32	0.17	0.19	0.0	-0.18	-0.32	0.6	0.39	-0.12	-0.62	-0.18	-0.17
Cash And Short Term Investments	0.57	0.59	-0.7	0.62	-0.69	0.81	-0.78	0.55	0.77	-0.12	0.16		0.71	0.12	0.79	-0.63	-0.38	0.56	-0.8	0.4	0.7	-0.22	0.93	-0.71	0.78	0.14
Net Receivables	0.69	0.72	-0.76	0.75	-0.55	0.72	-0.62	0.7	0.9	0.11	0.49	0.71		0.43	0.37	-0.69	-0.44	0.69	-0.82	0.46	0.97	-0.08	0.5	-0.77	0.51	0.23
Long Term Debt Total	-0.02	0.31	-0.09	-0.03	0.08	0.09	0.19	0.06	0.52	-0.34	0.91	0.12	0.43		-0.34	0.11	0.22	-0.01	-0.18	-0.36	0.55	0.16	-0.1	-0.63	-0.19	-0.2
Other Current Assets	0.67	0.5	-0.4	0.66	-0.78	0.83	-0.88	0.52	0.28	-0.12	-0.32	0.79	0.37	-0.34		-0.44	-0.21	0.67	-0.48	0.51	0.32	-0.24	0.94	-0.2	0.75	0.08
Total Liab	-0.54	-0.14	0.92	-0.68	0.23	-0.44	0.52	-0.33	-0.59	-0.45	0.17	-0.63	-0.69	0.11	-0.44		0.79	-0.53	0.87	-0.7	-0.61	0.46	-0.53	0.47	-0.69	-0.52
Short Long Term Debt	-0.2	-0.02	0.81	-0.34	-0.03	-0.12	0.35	-0.21	-0.39	-0.82	0.19	-0.38	-0.44	0.22	-0.21	0.79		-0.19	0.77	-0.78	-0.44	0.27	-0.31	0.22	-0.73	-0.89
Total Current Assets	1.0	0.69	-0.53	0.98	-0.8	0.88	-0.85	0.83	0.47	-0.03	0.0	0.56	0.69	-0.01	0.67	-0.53	-0.19		-0.56	0.57	0.63	0.07	0.56	-0.19	0.47	0.09
Short Term Debt	-0.57	-0.45	0.98	-0.68	0.4	-0.6	0.66	-0.55	-0.82	-0.36	-0.18	-0.8	-0.82	-0.18	-0.48	0.87	0.77	-0.56		-0.67	-0.84	0.16	-0.64	0.63	-0.81	-0.58
Common Stock	0.58	0.31	-0.67	0.66	-0.29	0.41	-0.64	0.44	0.24	0.74	-0.32	0.4	0.46	-0.36	0.51	-0.7	-0.78	0.57	-0.67		0.42	-0.25	0.47	-0.03	0.81	0.81
Property Plant Equipment	0.64	0.74	-0.77	0.68	-0.51	0.69	-0.6	0.7	0.93	0.11	0.6	0.7	0.97	0.55	0.32	-0.61	-0.44	0.63	-0.84	0.42		0.05	0.48	-0.77	0.52	0.29
Short Long Term Debt Total	0.06	0.35	0.16	-0.04	-0.27	0.03	-0.09	0.47	0.08	-0.19	0.39	-0.22	-0.08	0.16	-0.24	0.46	0.27	0.07	0.16	-0.25	0.05		-0.35	0.29	-0.33	-0.11
Property Plant And Equipment Net	0.56	0.49	-0.54	0.59	-0.68	0.8	-0.81	0.43	0.49	-0.11	-0.12	0.93	0.5	-0.1	0.94	-0.53	-0.31	0.56	-0.64	0.47	0.48	-0.35		-0.49	0.83	0.14
Net Debt	-0.2	-0.44	0.54	-0.27	0.25	-0.43	0.24	-0.23	-0.85	0.16	-0.62	-0.71	-0.77	-0.63	-0.2	0.47	0.22	-0.19	0.63	-0.03	-0.77	0.29	-0.49		-0.36	0.02
Non Current Assets Total	0.48	0.38	-0.75	0.56	-0.43	0.59	-0.75	0.41	0.46	0.42	-0.18	0.78	0.51	-0.19	0.75	-0.69	-0.73	0.47	-0.81	0.81	0.52	-0.33	0.83	-0.36		0.66
Non Currrent Assets Other	0.1	0.02	-0.6	0.2	0.15	-0.04	-0.25	0.13	0.16	0.92	-0.17	0.14	0.23	-0.2	0.08	-0.52	-0.89	0.09	-0.58	0.81	0.29	-0.11	0.14	0.02	0.66

Click cells to compare fundamentals

Trevi Therapeutics Account Relationship Matchups

Trevi Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	60.0M	47.1M	38.5M	123.0M	89.4M	56.3M
Other Current Liab	3.5M	3.4M	3.9M	3.5M	3.4M	3.2M
Total Current Liabilities	5.2M	5.6M	12.7M	13.4M	5.8M	7.3M
Total Stockholder Equity	54.5M	27.3M	17.1M	107.5M	82.5M	41.7M
Other Liab	325K	460K	196K	3K	2.7K	2.6K
Net Tangible Assets	54.5M	27.3M	17.1M	107.5M	123.6M	129.8M
Retained Earnings	(114.2M)	(147.0M)	(180.9M)	(210.1M)	(239.1M)	(227.2M)
Accounts Payable	1.6M	2.0M	2.8M	2.9M	1.8M	1.7M
Cash	57.3M	45.0M	36.8M	12.6M	32.4M	31.8M
Other Assets	1.6M	19K	759.0	334K	205K	0.0
Cash And Short Term Investments	57.3M	45.0M	36.8M	12.6M	83.0M	87.1M
Net Receivables	184K	558K	265K	241K	277.2K	243.5K
Common Stock Total Equity	101K	18K	19K	60K	69K	37.0K
Inventory	1.4M	1.6M	895K	(241K)	(277.2K)	(263.3K)
Other Current Assets	77K	108K	886K	2.1M	4.6M	4.8M
Other Stockholder Equity	168.7M	174.2M	198.0M	317.6M	321.6M	179.7M
Total Liab	5.5M	19.8M	21.4M	15.6M	6.9M	10.6M
Short Long Term Debt	5.3M	0.0	5.8M	7M	6.3M	4.2M
Total Current Assets	59.6M	46.3M	38.0M	122.6M	87.5M	55.5M
Accumulated Other Comprehensive Income	(23K)	(46K)	(60.0M)	(122K)	(29K)	(30.5K)
Short Term Debt	99K	113K	6.0M	7.0M	612K	581.4K
Common Stock	18K	19K	29K	60K	68K	41.7K
Property Plant Equipment	430K	330K	184K	170K	195.5K	201.5K
Property Plant And Equipment Net	430K	330K	184K	194K	1.6M	1.6M
Net Debt	(57.0M)	(30.8M)	(22.2M)	(3.4M)	(31.1M)	(32.6M)
Non Current Assets Total	449K	862K	518K	399K	1.9M	1.9M
Non Currrent Assets Other	19K	532K	334K	205K	297K	341.9K
Common Stock Shares Outstanding	11.7M	18.1M	22.8M	64.5M	99.0M	104.0M
Liabilities And Stockholders Equity	60.0M	47.1M	38.5M	123.0M	89.4M	63.0M
Non Current Liabilities Total	257K	14.3M	8.7M	2.2M	1.0M	980.4K
Net Invested Capital	54.5M	41.2M	31.6M	116.6M	82.5M	41.6M
Property Plant And Equipment Gross	430K	330K	366K	419K	1.7M	1.8M
Net Working Capital	54.4M	40.7M	25.2M	109.2M	81.7M	53.8M
Capital Stock	18K	19K	29K	60K	68K	39.3K

Currently Active Assets on Macroaxis

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America
S	SentinelOne
WD	Walker Dunlop

When determining whether Trevi Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Trevi Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Trevi Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Trevi Therapeutics Stock:

How To Invest In Trevi

Details

Is Trevi Stock a good investment?

Details

What is Trevi Therapeutics' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Trevi Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

For more detail on how to invest in Trevi Stock please use our How to Invest in Trevi Therapeutics guide.

You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Trevi Therapeutics. If investors know Trevi will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Trevi Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.44)

Return On Assets

(0.37)

Return On Equity

(0.60)

The market value of Trevi Therapeutics is measured differently than its book value, which is the value of Trevi that is recorded on the company's balance sheet. Investors also form their own opinion of Trevi Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Trevi Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Trevi Therapeutics' market value can be influenced by many factors that don't directly affect Trevi Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Trevi Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Trevi Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Trevi Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Trevi Cash Per Share vs Pfcf Ratio Analysis

Cash Per Share vs Pfcf Ratio

Cash Per Share vs Pfcf Ratio Correlation Analysis

Correlation Coefficient

Cash Per Share

Pfcf Ratio

Trevi Therapeutics fundamental ratios Correlations

Trevi Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Trevi Therapeutics fundamental ratios Accounts

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Total Stockholder Equity	+ 0.98	Total Assets
Short Term Debt	+ 0.98	Total Current Liabilities
Total Current Assets	+ 0.98	Total Stockholder Equity
Property Plant Equipment	+ 0.97	Net Receivables
Property Plant And Equipment Net	+ 0.94	Other Current Assets

Net Tangible Assets	- 0.93	Other Liab
Retained Earnings	- 0.92	Net Tangible Assets
Non Currrent Assets Other	- 0.89	Short Long Term Debt
Other Current Assets	- 0.88	Retained Earnings
Accounts Payable	- 0.88	Other Liab
Retained Earnings	- 0.86	Total Assets